By Sagar Lonial and
155 pages, 24 illustrations
$25.00 (Our delivery cost is a flat fee of $9.00 so the more you order the better!)
Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies.
This second edition of Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias includes:
- the new IMWG SLiM CRAB criteria
- the latest advances in diagnostic tests and imaging
- cytogenetics and genetic profiling
- induction therapy prior to SCT
- new lenalidomide- and bortezomib-based regimens
- second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments.
This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice.
Professor, Emory School of Medicine; Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology;
Director, Translational Research, B-cell Malignancy Program, Winship Cancer Institute, Emory University, Atlanta, GA, USA
Consultant Haematologist, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK
Are you a healthcare professional?
Have you taken the FastTest for this title?
Thank you for your feedback
Feel free to leave a comment for the authors below.
If you haven't already, don't forget to take the FastTest for this title.
Good health decisions